Thomas Hope

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Thomas Hope sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 5 currently recruiting 7 completed early-phase tilt top decile by trial count

Thomas Hope: 13 sponsored US clinical trials, 5 recruiting.

Thomas Hope sponsors 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Very High Risk Prostate Carcinoma, with 1 trials.

Top-decile sponsor footprint

Thomas Hope ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the Thomas Hope pipeline

5 recruiting of 13 indexed (38% open); 7 completed (54%).

Phase mix: 3 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Very High Risk Prostate Carcinoma (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Thomas Hope: open-pipeline peers nationwide

Peers matched on 13 registered trials and 38% open enrollment, not the therapeutic-area sidebar.

Thomas Hope sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1020304050 0%10%20%30%40%50% Total trials Recruiting share Thomas HopeAdaptimmuneAgennixAkili Interactive LabsAlumisMorehouse School of MedicineNortheastern UniversityWilliam StoopsXenon Pharmaceuticals
Thomas Hope sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Thomas Hope sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 38% open enrollment (± trial volume)

What to do with this Thomas Hope page

13 registered trials is a research-attention snapshot, not an endorsement of Thomas Hope or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Thomas Hope pipeline card: 13 registered trials from official public datasets.Report a data error.